gastroenteropancreatic neuroendocrine tumours
Oncology · 2015–2016
2decisions
1medicine
2carried consumer input
141individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lanreotide Treatment of non-functional gastroenteropancreatic neuroendocrine tumours (GEP-NETs) with unresectable locally advanced disease or metastatic disease that are… | Nov 2016 | Not recommended | 119 individuals Unicorn Foundation Australia |
| lanreotide Treatment of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adult patients with unresectable locally advanced or metastatic disease. | Nov 2015 | Not recommended | 22 individuals |
Who spoke
Unicorn Foundation Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.